Accelerating access and scale-up of optimized ART in low-income and middle-income countries: a call for a coordinated end-to-end approach


    loading  Checking for direct PDF access through Ovid

Abstract

Purpose of reviewTo discuss how aligning the collective power of scientists, regulators, drug companies, donors, implementers and advocates to achieve a single goal – accelerating access to simpler, safer, more robust and more affordable HIV treatment – can rapidly advance antiretroviral optimization efforts and enable scale-up.Recent findingsHarmonization of traditionally sequential processes can address the delays commonly experienced in introducing new products to low-income and middle-income countries, by facilitating an ‘end-to-end’ approach that mitigates risk and encourages early planning for all aspects of product introduction.SummaryPlanning with the ‘end-in-mind’ can facilitate healthy markets, benefit the application of new technologies, and accelerate the development of improved products in parallel (versus traditionally sequential efforts).

    loading  Loading Related Articles